Cardiovascular health and mortality in Cushing's disease.
Cardiovascular Health
Cushing’s Disease
Hypercortisolemia
Mortality
Journal
Pituitary
ISSN: 1573-7403
Titre abrégé: Pituitary
Pays: United States
ID NLM: 9814578
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
08
07
2022
pubmed:
23
7
2022
medline:
26
10
2022
entrez:
22
7
2022
Statut:
ppublish
Résumé
Exposure to cortisol excess in Cushing's disease (CD) results in increased cardiovascular morbidity and reduces survival, with cardiovascular disease being a leading cause of death. At diagnosis, a significant number of patients have adverse cardiovascular profiles (e.g., obesity, diabetes or impaired glucose tolerance, dyslipidemia, hypertension, cardiac abnormalities and vascular disease). Remission of hypercortisolemia reduces but does not completely eliminate the cardiovascular complications; hazard ratios for myocardial infarction and stroke are high during long-term monitoring, highlighting the long-lasting effects of hypercortisolism and the importance of the timely diagnosis and successful management of this condition. Data on mortality of patients in remission are not consistent but in a multicenter study, an increased all-cause and circulatory mortality in patients with CD in remission for at least 10 years has been demonstrated. Cardiovascular morbidity requires particular focus and effective management during the care of patients with CD, from their presentation until long-term follow up.
Identifiants
pubmed: 35869339
doi: 10.1007/s11102-022-01258-4
pii: 10.1007/s11102-022-01258-4
pmc: PMC9587928
doi:
Substances chimiques
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
750-753Informations de copyright
© 2022. Crown.
Références
Clin Endocrinol (Oxf). 2012 Mar;76(3):332-8
pubmed: 21854405
J Clin Endocrinol Metab. 2019 Jun 1;104(6):2375-2384
pubmed: 30715394
Clin Endocrinol (Oxf). 2011 Sep;75(3):354-60
pubmed: 21521323
J Clin Endocrinol Metab. 2012 Apr;97(4):1194-201
pubmed: 22278423
J Clin Endocrinol Metab. 2012 May;97(5):1702-11
pubmed: 22419708
Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875
pubmed: 34687601
J Clin Endocrinol Metab. 2013 Jun;98(6):2277-84
pubmed: 23533241
Best Pract Res Clin Endocrinol Metab. 2021 Jan;35(1):101521
pubmed: 33766428
Eur J Endocrinol. 2013 Oct 08;169(5):715-23
pubmed: 23996696
Clin Endocrinol (Oxf). 2010 Oct;73(4):469-75
pubmed: 20550536
Neuroendocrinology. 2010;92 Suppl 1:44-9
pubmed: 20829617
Eur J Endocrinol. 2021 Apr 22;184(5):R207-R224
pubmed: 33539319
Lancet Diabetes Endocrinol. 2016 Jul;4(7):569-76
pubmed: 27265184
J Clin Endocrinol Metab. 1999 Aug;84(8):2664-72
pubmed: 10443657
J Clin Endocrinol Metab. 2014 Nov;99(11):E2144-53
pubmed: 25093618
Neuroendocrinology. 2010;92 Suppl 1:86-90
pubmed: 20829625
J Clin Endocrinol Metab. 2003 Jun;88(6):2527-33
pubmed: 12788849